<DOC>
	<DOCNO>NCT00705016</DOCNO>
	<brief_summary>The purpose open-label , randomize , control , Phase 1/2 study integrin inhibitor cilengitide evaluate safety efficacy combination different regimen cilengitide add cisplatin , 5-fluorouracil ( 5-FU ) , cetuximab participant recurrent/metastatic squamous cell carcinoma head neck ( SCCHN ) . The Phase 1 part conduct dedicate study center . In Phase 2 part trial , cilengitide administer two different dos two experimental group . The third group receive cisplatin , 5-FU cetuximab . In Phase 1 part trial , dose cilengitide combination cisplatin , 5-FU cetuximab determine . Cilengitide experimental anti-cancer substance interact so-called integrins . Integrins protein molecule know present surface certain cancer cell . Integrins also find certain cell belong grow blood vessel ( endothelial cell ) . Integrins potentially facilitate blood vessel ' support tumor ( angiogenesis ) well tumor 's growth spread throughout body ( metastasis ) . By inhibit integrins tumor cell surface , cilengitide potentially kill cancer cell , potentially sensitizes cancer cell co-administered therapeutic . By inhibit integrins endothelial cell surface , potentially inhibit ingrowth additional blood vessel towards tumor . Cilengitide give intravenous infusion ( give drip one vein arm ) . If unacceptable side effect occur , treatment study drug stop .</brief_summary>
	<brief_title>Cilengitide Recurrent and/or Metastatic Squamous Cell Carcinoma Head Neck ( SCCHN )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis SCCHN At least one measurable lesion either computerize tomography ( CT ) scan magnetic resonance imaging ( MRI ) Karnofsky performance status ( KPS ) great equal 70 eastern cooperative oncology group performance status ( ECOG PS ) 01 trial entry Prior systemic chemotherapy , except give part multimodal treatment locally advanced disease , complete 6 month prior trial entry Surgery ( exclude prior diagnostic biopsy ) irradiation within 4 week trial entry Nasopharyngeal Carcinoma Documented symptomatic brain leptomeningeal metastasis Previous treatment epidermal growth factor receptor ( EGFR ) target therapy signal transduction inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Randomized treatment</keyword>
	<keyword>open-label</keyword>
	<keyword>control</keyword>
	<keyword>recurrent</keyword>
	<keyword>metastatic</keyword>
	<keyword>SCCHN</keyword>
	<keyword>suitable</keyword>
	<keyword>local therapy</keyword>
</DOC>